AOD-9604 + CJC-1295 + Ipamorelin Triple Blend
This triple blend combines AOD-9604 (HGH fragment for lipolysis), CJC-1295 No DAC (pulsatile GHRH), and Ipamorelin (selective GHRP) in a single vial. The synergistic combination addresses GH pulsatility, GH-mediated lipolysis, and fat-specific receptor activity simultaneously — studied for body composition research.
⚡ QUICKSTART HIGHLIGHTS
Dosing & Reconstitution Guide
| Vial | BAC Water | Total Conc. | Per Component | mcg per Unit |
|---|---|---|---|---|
| 12 mg blend | 3.0 mL | 4.0 mg/mL total | ~1.33 mg/mL each (4mg each) | ~13.3 mcg each per unit |
Dosing Protocol
| Phase | Total Daily Dose | Units | Volume | Notes |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 600 mcg total | 15 units | 0.15 mL | 200 mcg of each component |
| Weeks 3–4 | 900 mcg total | 22.5 units | 0.225 mL | 300 mcg each |
| Weeks 5+ | 1,200 mcg total | 30 units | 0.30 mL | 400 mcg each — standard research dose |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the blend vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within the window specified above.
How This Works
This triple blend leverages three complementary GH-pathway mechanisms. AOD-9604 is fragment 176–191 of HGH — the C-terminal region responsible for HGH's fat-metabolizing activity without IGF-1 stimulation or glucose intolerance. It stimulates lipolysis via β3-adrenergic receptors and inhibits lipogenesis independently of the GH receptor.
CJC-1295 No DAC stimulates the GHRH receptor at the pituitary, amplifying the amplitude of GH pulses. Ipamorelin stimulates ghrelin receptors (GHS-R1a) at both pituitary and hypothalamus, increasing GH pulse frequency and amplitude. Combined, CJC+Ipamorelin produce synergistic GH release while AOD-9604 provides direct fat-specific lipolytic activity downstream.
Potential Benefits & Side Effects
Potential Benefits
- Triple mechanism: GHRH amplification + ghrelin stimulation + direct lipolysis.
- AOD-9604 provides fat-targeted lipolysis without insulin resistance or IGF-1 elevation.
- Fasted state enhances all three components' effectiveness.
- Convenient single-vial formulation vs three separate injections.
- CJC + Ipamorelin synergy well-characterized in secretagogue literature.
Side Effect Profile
- Mild water retention early (GH-mediated).
- Fatigue or morning grogginess if dosed at night.
- Injection-site reactions.
- WADA prohibited — all three components.
- Nausea at higher doses (rare).
- Avoid with active malignancy.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | −20°C, up to 24 months |
| Reconstituted | 2–8°C | Up to 14 days |